J&J’s Biotech Strategy Balances Partnerships and Acquisitions for Oncology Growth
AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.
You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.
J&J's Biotech Strategy Balances Partnerships and Acquisitions for Oncology Growth
- Johnson & Johnson has strategically built its pharmaceutical portfolio, particularly in oncology, through partnerships and targeted acquisitions, exemplified by securing rights to the CAR-T therapy Carvykti in 2017 for an upfront payment of $350 million.
- This approach has also led to situations like the co-ownership of the blood-cancer drug Imbruvica after partner Pharmacyclics was acquired by AbbVie in 2015 for $21 billion, following J&J's initial investment of less than $1 billion for half of the profits.
Full Summary — powered by AI
Johnson & Johnson has cultivated a distinct strategy for expanding its oncology pipeline, prioritizing strategic partnerships and “early-stage deals” over large-scale, multi-billion-dollar acquisitions. This approach aims to secure promising therapeutic assets at more favorable costs, allowing J&J to share development risks while retaining significant upside potential.
A notable success of this strategy is Carvykti (ciltacabtagene autoleucel), a CAR-T cell therapy for multiple myeloma. J&J partnered with Legend Biotech in 2017, acquiring rights for an upfront payment of $350 million. Carvykti has since become a leading CAR-T therapy, generating nearly $2 billion in sales in 2025. Another significant collaboration involved the blood-cancer drug Imbruvica (ibrutinib), where J&J initially paid less than $1 billion for half the profits from its partner, Pharmacyclics. However, this partnership evolved into a “corporate marriage” with AbbVie after AbbVie acquired Pharmacycl